Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Assets (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Assets for 8 consecutive years, with $93.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets fell 38.99% to $93.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $93.5 million, a 38.99% decrease, with the full-year FY2024 number at $136.4 million, down 14.64% from a year prior.
  • Assets was $93.5 million for Q3 2025 at Precision Biosciences, down from $108.9 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $297.2 million in Q2 2022 to a low of $93.5 million in Q3 2025.
  • A 5-year average of $189.3 million and a median of $181.7 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: surged 40.85% in 2021, then crashed 39.52% in 2023.
  • Precision Biosciences' Assets stood at $211.5 million in 2021, then grew by 12.61% to $238.2 million in 2022, then crashed by 32.91% to $159.8 million in 2023, then decreased by 14.64% to $136.4 million in 2024, then tumbled by 31.44% to $93.5 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Assets are $93.5 million (Q3 2025), $108.9 million (Q2 2025), and $124.4 million (Q1 2025).